MedTrace Logo

A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients

NCT06707246 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-11-27

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the efficacy secukimumab versus tofacitinib in patients with moderate to severe hidradenitis suppurativa (HS)in adults. It will also learn about the safety of secukimumab and tofacitinib. The main questions it aims to answer are:

* Which treatment is more effective in patients with moderate to severe HS?
* What medical problems do participants have when taking secukimumab versus tofacitinib? Researchers will compare secukimumab versus tofacitinib to see which treatment works better to treat moderate to severe HS.

Participants will:

* Half of participants will take secukimumab every week in the first month and every four weeks thereafter till 1 year
* Another half of participants will take tofacitinib a tablet daily for 1 year
* Visit the clinic once every 2 weeks for checkups and tests in the first month, and every 4 weeks thereafter
* Keep a diary of their symptoms and the number of times they use a rescue inhaler

Conditions

Interventions

DRUG

Secukinumab 300 MG; Tofacitinib 11mg

Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml

Sponsors & Collaborators

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Jinhua Central Hospital

    collaborator OTHER

  • Affiliated Hospital of Jiaxing University

    collaborator OTHER

  • Ningbo No. 1 Hospital

    collaborator OTHER

  • The First People's Hospital of Huzhou

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-15
Primary Completion
2026-10-31
Completion
2027-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06707246 on ClinicalTrials.gov